Truist lowered the firm’s price target on RadNet (RDNT) to $74 from $88 and keeps a Buy rating on the shares as part of a broader research note previewing Q1 results in Healthcare Services and adjusting the firm’s models. The sector looks relatively well positioned in a fluid environment given the scaled, largely domestic, attractive free cash flow generating, defensive nature of the group, and while regulatory developments remain an area of focus, the Medicare Advantage final rule reinforced the firm’s expectation of a better environment, the analyst tells investors in a research note.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RDNT:
- RadNet price target lowered to $60 from $74 at Barclays
- Aclarion announces expansion plans with RadNet affiliates in NY, NJ
- RadNet Achieves Record Revenue in 2024
- RadNet upgraded to Strong Buy at Raymond James as valuation ‘more compelling’
- RadNet upgraded to Strong Buy from Outperform at Raymond James